<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36725047</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7235</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>18</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Internal medicine (Tokyo, Japan)</Title><ISOAbbreviation>Intern Med</ISOAbbreviation></Journal><ArticleTitle>Antiphospholipid Syndrome Nephropathy with Acute Thrombotic Microangiopathy after Renal Transplantation.</ArticleTitle><Pagination><StartPage>2707</StartPage><EndPage>2713</EndPage><MedlinePgn>2707-2713</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.0813-22</ELocationID><Abstract><AbstractText>We experienced a 36-year-old man with lupus nephritis and antiphospholipid syndrome (APS) who received a donor kidney from his father. Twenty-two months after transplantation, at a time of poor adherence to immunosuppressants and warfarin, the patient developed sudden graft loss due to hemolytic uremic syndrome with rapid deterioration of renal function, thrombocytopenia, and hemolytic anemia. A kidney biopsy showed thrombotic microangiopathy (TMA) related to platelet thrombus formation; however, there was no recurrence of lupus and no findings suggestive of post-transplant rejection, so acute TMA associated with APS was thought to be the cause of the graft loss. This case highlights the importance of instructing patients with lupus nephritis to adhere to treatment with warfarin, a therapeutic drug for APS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suenaga</LastName><ForeName>Atsuhiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, Saga University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawa</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miki</LastName><ForeName>Katsuyuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Takayoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuno</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikuma</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oba</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sekine</LastName><ForeName>Akinari</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamanouchi</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Eiko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwabe</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kono</LastName><ForeName>Kei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Toranomon Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinowaki</LastName><ForeName>Keiichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Toranomon Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohashi</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Toranomon Hospital, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Pathology, Tokyo Medical Dental University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>Kazuho</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Showa University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazono</LastName><ForeName>Motoaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Saga University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ubara</LastName><ForeName>Yoshifumi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Okinaka Memorial Institute for Medical Research, Toranomon Hospital Kajigaya, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Intern Med</MedlineTA><NlmUniqueID>9204241</NlmUniqueID><ISSNLinking>0918-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber><NameOfSubstance UI="D014859">Warfarin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057049" MajorTopicYN="Y">Thrombotic Microangiopathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="Y">Kidney Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">antiphospholipid syndrome nephropathy</Keyword><Keyword MajorTopicYN="N">lupus nephropathy</Keyword><Keyword MajorTopicYN="N">renal transplantation</Keyword><Keyword MajorTopicYN="N">thrombotic microangiopathy</Keyword></KeywordList><CoiStatement>
<b>The authors state that they have no Conflict of Interest (COI).</b>
</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>1</Day><Hour>20</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36725047</ArticleId><ArticleId IdType="pmc">PMC10569915</ArticleId><ArticleId IdType="doi">10.2169/internalmedicine.0813-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lionaki S, Skalioti C, Boletis JN. Kidney transplantation in patients with systemic lupus erythematosus. World J Transplant 4: 176-182, 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4208080</ArticleId><ArticleId IdType="pubmed">25346890</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG. Antiphospholipid syndrome nephropathy: from pathogenesis to treatment. Front Immunol 9: 1181, 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990608</ArticleId><ArticleId IdType="pubmed">29904380</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienaim&#xe9; F, Legendre C, Terzi F, Canaud G. Antiphospholipid syndrome and kidney disease. Kidney Int 91: 34-44, 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">27555120</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya S. Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome. Clin Transplant 26: 853-856, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22507396</ArticleId></ArticleIdList></Reference><Reference><Citation>Loupy A, Haas M, Roufosse C, et al. . The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 20: 2318-2331, 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496245</ArticleId><ArticleId IdType="pubmed">32463180</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone JH, Amend WJ, Criswell LA. Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 34: 1040-1047, 1999.</Citation><ArticleIdList><ArticleId IdType="pubmed">10585313</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducloux D, Pellet E, Fournier V, et al. . Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 67: 90-93, 1999.</Citation><ArticleIdList><ArticleId IdType="pubmed">9921802</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier M, Canoui-Poitrine F, Gu&#xe9;ry E, et al. . Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey. Nephrol Dial Transplant 33: 709-716, 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">29346631</ArticleId></ArticleIdList></Reference><Reference><Citation>Canaud G, Bienaim&#xe9; F, No&#xeb;l LH, et al. . Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 10: 2051-2060, 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">20883539</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales JM, Serrano M, Martinez-Flores JA, Perez D, Serrano A. Antiphospholipid syndrome and renal allograft thrombosis. Transplantation 103: 481-486, 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">30376553</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 4: 1499-1515, 1994.</Citation><ArticleIdList><ArticleId IdType="pubmed">8025223</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Agati VD, Stokes MB. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogren's syndrome and Rheumatoid arthiritis. In: Heptinstall's Pathology of the Kidney. 7th ed. Jennette JC, D'Agati VD, Olson JL, Eds. Wolters Kluwer, Alphen upon Rhine, 2015: 559-655.</Citation></Reference><Reference><Citation>Sekine A, Hasegawa E, Hiramatsu R, et al. . Two types of renovascular lesions in lupus nephritis with clinical thrombotic thrombocytopenic purpura. Case Rep Nephrol Dial 5: 192-199, 2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4637818</ArticleId><ArticleId IdType="pubmed">26558253</ArticleId></ArticleIdList></Reference><Reference><Citation>Suenaga A, Sawa N, Oshima Y, et al. . Antiphospholipid syndrome nephropathy related disease diagnosed by assessing phosphatidylserine-dependent antiprothrombin antibodies. Intern Med 62: 757-761, 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037018</ArticleId><ArticleId IdType="pubmed">35908966</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol 3: 9-17, 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956908</ArticleId><ArticleId IdType="pubmed">24644537</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus 14: 499-504, 2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">16130503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>